Castle Biosciences Stock Retained Earnings
| CSTL Stock | USD 20.84 0.87 4.36% |
Fundamental analysis of Castle Biosciences allows traders to better anticipate movements in Castle Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Castle Biosciences Company Retained Earnings Analysis
Castle Biosciences' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Castle Biosciences Retained Earnings | (200.13 M) |
Most of Castle Biosciences' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Castle Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Castle Biosciences has a Retained Earnings of (200.13 Million). This is 121.49% lower than that of the Biotechnology sector and 130.78% lower than that of the Health Care industry. The retained earnings for all United States stocks is 102.15% higher than that of the company.
Castle Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Castle Biosciences' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics of similar companies.Castle Biosciences is currently under evaluation in retained earnings category among its peers.
Castle Fundamentals
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0279 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 335.21 M | ||||
| Shares Outstanding | 29.01 M | ||||
| Shares Owned By Insiders | 3.00 % | ||||
| Shares Owned By Institutions | 93.01 % | ||||
| Number Of Shares Shorted | 1.4 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 1.67 X | ||||
| Revenue | 332.07 M | ||||
| Gross Profit | 280.47 M | ||||
| EBITDA | 38.14 M | ||||
| Net Income | 18.25 M | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 26.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 15.71 X | ||||
| Cash Flow From Operations | 64.87 M | ||||
| Short Ratio | 3.77 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 35.63 | ||||
| Number Of Employees | 798 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 579.3 M | ||||
| Total Asset | 531.24 M | ||||
| Retained Earnings | (200.13 M) | ||||
| Working Capital | 310.76 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
| Net Asset | 531.24 M |
About Castle Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Castle Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Castle Biosciences Piotroski F Score and Castle Biosciences Altman Z Score analysis. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.